Showing results (1811-1820 of 1,970) with videos related to

Sort By:
Pageof 197
Plos One|October 12, 2016
Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal FluidDeepak K Kaushik, Heather Y F Yong, Jennifer N Hahn, et al.
JCO Oncology Practice|April 15, 2024
Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal AdenocarcinomaDerk C F Klatte, Jason S Starr, Kristin E Clift, et al.
Journal of the National Cancer Institute|August 16, 2011
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancerChee K Lee, Michael Friedlander, Chris Brown, et al.
Frontiers in Immunology|May 6, 2026
Gut microbial IgA coating in infants with traditional farming lifestyle and urban infants with allergic outcomesKevin Bu, Tyler Scherzi, Adam Cantor, et al.
Journal of the American College of Cardiology|January 12, 2001
Factors affecting long-term survival (>10 years) after cardiac transplantation in the cyclosporine eraR John, H A Rajasinghe, S Itescu, et al.
International Journal of Legal Medicine|June 17, 2008
Genomic complexity of the Y-STR DYS19: inversions, deletions and founder lineages carrying duplicationsPatricia Balaresque, Emma J Parkin, Lutz Roewer, et al.
Journal of Neurotrauma|June 13, 2015
Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Propensity Score-Matched Cohort Study from a Canadian Multi-Center Spinal Cord Injury RegistryNathan Evaniew, Vanessa K Noonan, Nader Fallah, et al.
Plos One|November 27, 2013
The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseasesMarie-Josée J Mangen, Dietrich Plass, Arie H Havelaar, et al.
Circulation|November 16, 2011
Pak1 as a novel therapeutic target for antihypertrophic treatment in the heartWei Liu, Min Zi, Ronald Naumann, et al.
American Heart Journal|June 24, 2010
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trialR John Simes, Rachel L O'Connell, Philip E Aylward, et al.
Pageof 197